Liam Cook - Nova Eye Chief Officer

EYE Stock

0.15 0.01 7.14%

Executive

Liam Cook is Chief Officer of Nova Eye Medical

Address	107 Rundle Street, Kent Town, SA, Australia, 5067
Phone	61 8 8362 0193
Web	https://www.nova-eye.com

Nova Eye Management Efficiency

The company has return on total asset (ROA) of (0.1861) % which means that it has lost $0.1861 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3949) %, meaning that it generated substantial loss on money invested by shareholders. Nova Eye's management efficiency ratios could be used to measure how well Nova Eye manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Nova Eye's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 40.5 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 2.1 M in 2024.

Compare Nova Eye to Peers

Predict price of Nova Eye

Nova Eye Medical has accumulated 3.35 M in total debt. Debt can assist Nova Eye until it has trouble settling it off, either with new capital or with free cash flow. So, Nova Eye's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nova Eye Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nova to invest in growth at high rates of return. When we think about Nova Eye's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			EXECUTIVE Age
	Jeffrey Ball	CSL	56
	Felicia Mayo	Block Inc	N/A
	Ethan Settembre	CSL	N/A
	Alexander Schirmeister	Xero	N/A
	Anthony Waldron	Rea Group	N/A
	Alyssa Henry	Block Inc	54
	Nicole Mehalski	Xero	N/A
	AMCT BA	Macquarie Group	59
	Gene Gander	WiseTech Global Limited	N/A
	John CPA	CSL	N/A
	Sean Lambright	Pro Medicus	N/A
	BEc FCIS	Xero	N/A
	BCom FCSA	CSL	55
	Christina Hickie	CSL	N/A
	Kirsty GodfreyBilly	Xero	N/A
	Katrina Johnson	WiseTech Global Limited	48
	Narelle Lynch	Tamawood	N/A
	Mark Rees	Xero	N/A
	Steven BE	Xero	66
	Sivan Whiteley	Block Inc	47
	Teresa Gschwind	Pro Medicus	N/A

Nova Eye Medical (EYE) is traded on Australian Securities Exchange in Australia and employs 14 people. Nova Eye is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

	Return On Equity	-0.39
	Return On Asset	-0.19

Nova Eye Medical Leadership Team

Elected by the shareholders, the Nova Eye's board of directors comprises two types of representatives: Nova Eye inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nova. The board's role is to monitor Nova Eye's management team and ensure that shareholders' interests are well served. Nova Eye's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nova Eye's outside directors are responsible for providing unbiased perspectives on the board's policies.

	BSc FAICD, Advisor Board
	BSc AM, MD Director
	Keith Byrne, Vice Operations
	BEc CA, Company Secretary
	Bill Swaim, Pres Ellex
	Mark Flynn, Investor Relations
	BEng BE, Founder Chairman
	Liam Cook, Chief Officer
	Joaquin Wolff, President iTrack
	Kate Hunt, Head Marketing
	Victor Previn, Founder Chairman
	David MD, Chief Officer
	Kimberley Menzies, Group Manager
	Don Watton, Vice Service

Nova Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nova Eye a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.39
	Return On Asset	-0.19
	Profit Margin	(0.38) %
	Operating Margin	(0.26) %
	Current Valuation	30.41 M
	Shares Outstanding	229.06 M
	Shares Owned By Insiders	18.59 %
	Shares Owned By Institutions	18.74 %
	Price To Book	1.56 X
	Price To Sales	1.52 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Nova Stock Analysis

When running Nova Eye's price analysis, check to measure Nova Eye's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nova Eye is operating at the current time. Most of Nova Eye's value examination focuses on studying past and present price action to predict the probability of Nova Eye's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nova Eye's price. Additionally, you may evaluate how the addition of Nova Eye to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC